Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.
A wide range of comorbidities present a challenge in treating psoriatic arthritis.
With more than a third of severe psoriatic arthritis patients considered obese, individuals with the disease also have a high rate of cardiovascular disease, depression, and liver disease like nonalcoholic steatohepatitis (NASH).
NASH might be particularly difficult because there currently is not a way to diagnose the disease without an invasive procedure such as a liver biopsy.
The very few treatments available, which tend to wane in effectiveness over the course of time for individuals, only add to the challenge in treating the life-long disease.
Vibeke Strand, MD, adjunct clinical professor in the Division of Immunology/Rheumatology at Stanford University, explained in an interview with HCPLive® why psoriatic arthritis is so difficult to treat.
However, 1 treatment that has had an impact on patients in recent years is adalimumab, an anti-TNF medication.
In data, which were published as part of the European E-Congress of Rheumatology 2020 (EULAR 2020) meeting, adalimumab was assessed in comparison to placebo in patients with severely active psoriatic arthritis.
Strand, who was an author on the study, said adalimumab is one of the more effective treatments for this disease, but there remains gaps in treatment caused by comorbidities.